Applications of Nanotechnology in Multiple Sclerosis by Respiratory Samples

Launched by CARMEL MEDICAL CENTER · Sep 20, 2010

Keywords

ClinConnect Summary

Multiple Sclerosis (MS) is a complex multi-factorial disease, with underlying both genetic and environmental factors. Different populations have different susceptibility. The disease is characterized by 2 main phenotypes: relapsing-remitting or progressive course. Clinical disability is due to distraction of the CNS myelin (mainly oligodendrocytes) due to 3 processes:

1. Inflammation- immune cells with aberrant activity invade the brain and spinal cord and cause distraction of CNS myelin.
2. Primary neurodegeneration - without prominent inflammation
3. Repair - the inflammatory and neurode...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• MS patients:
• • 1. Relapsing remitting (RRMS) meeting the clinical criteria of McDonald (Polman, Reingold et al. 2005) that presented in the MS clinic in Carmel hospital, Haifa Israel. Relapsing MS patients that never received, or have received in the past, or, are currently receiving, or, are about to commence immunomodulator treatment.
• • 2. MS patients presenting in acute relapse and about to commence a treatment regimen of corticosteroids (IV-Methylprednisolone and oral prednisone)
• • 3. Primary progressive (PPMS) meeting the clinical criteria of McDonald (Polman, Reingold et al. 2005)that presented in the MS clinic in Carmel hospital, Haifa Israel. Tissue will be collected as previously described.
• • 4. Willing and able to give inform consent
• Control subjects:
• • 1. Age and gender match control individuals that do not have MS or any other condition that is defined as "autoimmune". These individuals will be recruited as "Healthy Population Reference" group.
• • 2. Willing and able to give informed consent
• Exclusion Criteria:
• • 1. Patients age 18 or less, pregnant women
• • 2. Presence of HIV, hepatitis or any other potentially severe and infectious disease. Healthy individual with up to third degree relatives with MS or any other autoimmune diseases.
• Exclusion from the experiment during the study period:
• • 1. Any new clinical information that is not consistent with inclusion criteria.
• • 2. Technical problems in the performance of the tests.